Seven Arizona-based research teams have been awarded $100,000 grants from the Flinn Foundation as members of the 2026 Translational Seed Grants Program cohort. The new awardees represent six institutions — two from Arizona State University and one each from HonorHealth Research Institute, Mayo Clinic Arizona, Northern Arizona University, Translational Genomics Research Institute, or TGen, and University of Arizona. Barrow Neurological Institute, Black Canyon Bio, Smile Train, University of California, Davis, NAU, UCLA and Ohio State University all serve as partners on the projects, which address conditions including Valley fever, epilepsy, cleft conditions, and brain cancer.Continue reading
Category Archives: AZBio News
AZBio Member Spotlight – Bright Path Labs
Based in Mesa, Arizona, Bright Path is advancing pharmaceutical innovation by strengthening domestic manufacturing and addressing critical supply chain challenges. Through cutting-edge technology and a commitment to sustainability, the company is working to ensure patients have reliable access to essential medicines.Continue reading
AZAdvances Health Innovation Showcase Highlights Arizona’s Growing Bioscience Ecosystem
The AZAdvances Health Innovation Showcase featured an exciting lineup of Arizona-based innovators revolutionizing the future of healthcare through technologies, data solutions, and patient-focused strategies. During the event, numerous companies across diagnostics, digital health, therapeutics, and care delivery presented their ideas and visions for the future.Continue reading
GATC Health and UC Irvine Announce Landmark PNAS Publication Validating AI-Platform for Opioid Use Disorder Treatment
GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, and researchers from the University of California, Irvine (UCI) today announced the publication of a joint study in the Proceedings of the National Academy of Sciences (PNAS). The peer-reviewed paper validates a novel drug candidate, GATC-1021, which was identified using GATC Health’s Operon™ AI platform to more precisely target the specific neurological dysregulations found in individuals with Opioid Use Disorder (OUD).Continue reading
AZBio Member Spotlight – Precision Epigenomics
Precision Epigenomics focuses on addressing cancer by targeting epigenetic changes (i.e., DNA methylation) that drive tumor development, progression, and treatment resistance. While genetic mutations have long been a focus in oncology, epigenetic dysregulation plays a critical role in how cancer cells behave, adapt, and evade therapy. Their work centers on using their understanding of DNA methylation to develop new and innovative diagnostic tests to detect cancer earlier.Continue reading
HonorHealth CEO Todd LaPorte named W. P. Carey’s Executive of the Year
TEMPE, Ariz., April 2, 2026 /PRNewswire/ — With more than 40 years of diverse health care experience, Todd LaPorte has led HonorHealth through growth, innovation, and expanded access to high-quality care across the Phoenix metropolitan area. As CEO since 2017, LaPorte oversees an integrated health system that includes nine acute-care hospitals, hundreds of outpatient facilities, a research institute, a behavioral health hospital, a rehabilitation hospital, and a wide range of community services addressing social determinants of health and military preparedness.Continue reading
Arteris Bio Relocates into UA Tech Park to Advance Novel Topical Technology Platform
TUCSON, Ariz. – The University of Arizona (UA) Tech Park is pleased to welcome Arteris Bio, a life sciences company developing advanced topical technologies focused on skin physiology, microcirculation, and peripheral comfort. The company is led by founder and CEO Bruce Register, Ph.D., whose more than 30 years of experience span scientific research, global pharmaceutical leadership, and entrepreneurial ventures.Continue reading
Poll: U.S. voters want PBM and insurance reform—and strong biotech
Voters see a better path than Most Favored Nation to ensure access and affordability of innovative medicines
AZBio Member Spotlight – AquaLung Therapeutics
Aqualung Therapeutics is a biotechnology company based in Arizona focused on developing novel therapies that target inflammation and fibrosis. The team at Aqualung is working to advance treatments for critically ill patients, including those living with conditions such as Acute Respiratory Distress Syndrome (ARDS).Continue reading
AZBioPEERS – Turning Conferences Into Catalysts
Conferences can be powerful tools for visibility, relationship-building, and growth—but only with the right strategy.
This AZBioPEERS session focuses on how biotech and bioscience companies can effectively leverage conferences to advance their goals. Continue reading